Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome Sequencing

Cyril Pottier^{1,2,3,4,5,*}, Fahri Küçükali^{2,3}, Matt Baker¹, Anthony Batzler⁶, Gregory D. Jenkins⁶, Marka van Blitterswijk¹, Cristina T. Vicente^{2,3}, Wouter De Coster^{2,3}, Sarah Wynants^{2,3}, Pieter Van de Walle^{2,3}, Owen A. Ross¹, Melissa E. Murray¹, Júlia Faura^{2,3}, Stephen J. Haggarty⁷, Jeroen GJ. van Rooij⁸, Merel O. Mol⁸, Ging-Yuek R. Hsiung⁹, Caroline Graff^{10,11}, Linn Öijerstedt^{10,11}, Manuela Neumann^{12,13}, Yan Asmann¹⁴, Shannon K. McDonnell⁶, Saurabh Baheti⁶, Keith A. Josephs¹⁵, Jennifer L. Whitwell¹⁶, Kevin F. Bieniek^{1,17}, Leah Forsberg¹⁵, Hilary Heuer¹⁸, Argentina Lario Lago¹⁸, Ethan G. Geier¹⁸, Jennifer S. Yokoyama¹⁸, Alexis P. Oddi¹⁸, Margaret Flanagan¹⁷, Qinwen Mao¹⁹, John R. Hodges²⁰, John B. Kwok^{21,22}, Kimiko Domoto-Reilly²³, Matthis Synofzik^{12,24}, Carlo Wilke^{12,24}, Chiadi Onyike²⁵, Bradford C. Dickerson²⁶, Bret M. Evers²⁷, Brittany N. Dugger²⁸, David G. Munoz^{29,30}, Julia Keith^{30,31}, Lorne Zinman³¹, Ekaterina Rogaeva³², EunRan Suh³³, Tamar Gefen³⁴, Changiz Geula³⁴, Sandra Weintraub³⁴, Janine Diehl-Schmid^{35,36}, Martin R. Farlow³⁷, Dieter Edbauer³⁸, Bryan K. Woodruff³⁹, Richard J. Caselli³⁹, Laura L. Donker Kaat⁴⁰, Edward D. Huey⁴¹, Eric M. Reiman⁴², Simon Mead⁴³, Andrew King^{44,45}, Sigrun Roeber⁴⁶, Alissa L. Nana¹⁸, Nilufer Ertekin-Taner^{1,47}, David S. Knopman¹⁵, Ronald C. Petersen¹⁵, Leonard Petrucelli¹, Ryan J. Uitti⁴⁷, Zbigniew K. Wszolek⁴⁷, Eliana Marisa Ramos⁴⁸, Lea T. Grinberg¹⁸, Maria Luisa Gorno Tempini¹⁸, Howard J. Rosen⁴⁹, Salvatore Spina¹⁸, Olivier Piguet⁵⁰, Murray Grossman⁵¹, John Q. Trojanowski³³, Dirk C. Keene⁵², Jin Lee-Way⁵³, Johannes Prudlo^{54,55}, Daniel H. Geschwind⁴⁸, Robert A. Rissman⁵⁶, Carlos Cruchaga⁵⁷, Bernardino Ghetti⁵⁸, Glenda M. Halliday²¹, Thomas G. Beach⁵⁹, Geidy E. Serrano⁵⁹, Thomas Arzberger^{46,60}, Jochen Herms^{38,46}, Adam L. Boxer¹⁸, Lawrence S. Honig⁶¹, Jean P. Vonsattel⁶², Oscar L. Lopez⁶³, Julia Kofler⁶⁴, Charles L. White III²⁷, Marla Gearing⁶⁵, Jonathan Glass⁶⁵, Jonathan D. Rohrer⁶⁶, David J. Irwin⁵¹, Edward B. Lee³³, Vivianna Van Deerlin³³, Rudolph Castellani⁶⁷, Marsel M. Mesulam³⁴, Maria C. Tartaglia³², Elizabeth C. Finger⁶⁸, Claire Troakes⁴⁴, Safa Al-Sarraj^{44,69}, Bruce L. Miller¹⁸, Harro Seelaar⁸, Neill R. Graff-Radford⁴⁷, Bradley F. Boeve¹⁵, Ian RA. Mackenzie⁷⁰, John C. van Swieten⁸, William W. Seeley¹⁸, Kristel Sleegers^{2,2}, Dennis W. Dickson¹, Joanna M. Biernacka^{6,71}, Rosa Rademakers^{1,2,3,*}

† In memoriam

* Corresponding Authors

Rosa Rademakers, Ph.D. (ORCID: 0000-0002-4049-0863)

VIB Center for Molecular Neurology

Universiteitsplein 1, 2610 Wilrijk, Belgium

Phone: +32 3 265 95 95

E-mail: rosa.rademakers@uantwerpen.vib.be

Cyril Pottier, Ph.D.

Department of Neurology, Washington University School of Medicine

St Louis, MO, United States of America

Phone: +1 314 747 2601

E-mail: <u>cpottier@wustl.edu</u>

¹Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States of America
²Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
³VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
⁴Department of Neurology, Washington University School of Medicine, St Louis, MO, United States of America
⁵NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, United States of America
⁶Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, United States of America
⁷Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA,

02114, United States of America

⁸Department of Neurology, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 CN, The

Netherlands

⁹Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, V6T 2B5, Canada

¹⁰Division of Neurogeriatrics, Karolinska Institutet, Bioclinicum J10:20, Visionsgatan 4, Solna, 171 64, Sweden

¹¹Unit for Hereditary Dementias, Karolinska University Hospital, Solna, 171 64, Sweden

¹²German Center for Neurodegenerative Diseases (DZNE), Tübingen, 72076, Germany

¹³Department of Neuropathology, University of Tübingen, Tübingen, 72076, Germany
¹⁴Department of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States of America

¹⁵Department of Neurology, Mayo Clinic, Rochester, MN, 55905, United States of America
¹⁶Department of Radiology, Mayo Clinic, Rochester, MN, 55905, United States of America
¹⁷University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, United States of America

¹⁸Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, 94158, United States of America

¹⁹Department of Pathology, University of Utah, Salt Lake City, UT, 84112, United States of America

²⁰Central Clinical School and Brain and Mind Centre, University of Sydney, Sydney, 2050, Australia

²¹University of Sydney, Sydney, 2050, Australia

²²NeuRA, University of New South Wales, Randwick, 2031, Australia

²³Department of Neurology, University of Washington, 325 9th Ave, Seattle, WA, 98104, United States of America

²⁴Division Translational Genomics of Neurodegenerative Diseases, Center for Neurology and Hertie-

Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

²⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, 21218, United States of America

²⁶Department of Neurology, Case Western Reserve University, Cleveland, OH, 44106, United States of America

²⁷Division of Neuropathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd,

Dallas, TX, 75390-9073, United States of America

²⁸Department of Pathology and Laboratory Medicine, University of California, Davis Medical Center,

Sacramento, CA, 95817, United States of America

²⁹St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada

³⁰Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S 1A1, Canada

³¹Sunnybrook Health Sciences Centre, Toronto, ON, M4N 3M5, Canada

³²Krembil Discovery Tower, Tanz Centre for Research in Neurodegenerative Disease, University of

Toronto, 60 Leonard Av, Toronto, ON, M5T 0S8, Canada

³³Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research,

Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States of America

³⁴Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University, Chicago,

IL, 60611, United States of America

³⁵Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich, 80333, Germany

³⁶kbo-Inn-Salzach-Klinikum, Clinical Center for Psychiatry, Psychotherapy, Psychosomatic Medicine, Geriatrics and Neurology, Wasserburg/Inn, 83512, Germany

³⁷Department of Neurology, Indiana University School of Medicine, 355 West 16th Street, Indianapolis,

IN, 46202, United States of America

³⁸German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Str 17, Munich, 81377,

Germany

³⁹Department of Neurology, Mayo Clinic, Scottsdale, AZ, 85259, United States of America

⁴⁰Department of Clinical Genetics, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 CN, The Netherlands

⁴¹Department of Psychiatry and Human Behavior, Brown Alpert Medical School, Brown University, Providence, RI, 02912, United States of America

⁴²Banner Alzheimer's Institute, Phoenix, AZ, 85006, United States of America

⁴³MRC Prion Unit at University College London, Institute of Prion Diseases, London, United Kingdom
⁴⁴Department of Basic and Clinical Neuroscience, London Neurodegenerative Diseases Brain Bank,
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, United Kingdom

⁴⁵Department of Clinical Neuropathology, King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom

⁴⁶Centre for Neuropathology and Prion Research, Ludwig-Maximilians-University of Munich, Feodor-Lynen-Straße 23, Munich, 81377, Germany

⁴⁷Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, United States of America

⁴⁸Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, 90095, United States of America

⁴⁹Department of Pathology, UCSF Weill Institute for Neurosciences, University of California, San

Francisco, San Francisco, CA, 94158, United States of America

 ⁵⁰School of Psychology and Brain and Mind Centre, University of Sydney, Sydney, 2050, Australia
⁵¹Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States of America
⁵²University of Washington BioRepository and Integrated Neuropathology (BRaIN) lab, Harborview Medical Center, 325 9th Ave, Seattle, WA, 98104, United States of America
⁵³M.I.N.D. Institute Laboratory, University of California, Davis Medical Center, 2805 50th St, Sacramento, CA, 95817, United States of America
⁵⁴German Center for Neurodegenerative Diseases (DZNE), Rostock, 18147, Germany

⁵⁵Department of Neurology, Rostock University Medical Center, Rostock, 18147, Germany

⁵⁶Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA, USA

⁵⁷Department of Psychiatry, Knight Alzheimer Disease Research Center, Washington University School of Medicine, Saint Louis, MO, 63108, United States of America

⁵⁸Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN, 46202, United States of America

⁵⁹Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, 85351, United States of America

⁶⁰Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-University of Munich, Munich, 81377, Germany

⁶¹Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York, NY, 10032, United States of America

⁶²Department of Pathology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York, NY, 10032, United States of America

⁶³Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of America
⁶⁴Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of America
⁶⁵Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University, Atlanta, GA, 30322, United States of America

⁶⁶Department of Neurodegenerative Disease, Dementia Research Centre, University College London Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom

⁶⁷Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611,

United States of America

⁶⁸Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, N6A 2E2, Canada


⁶⁹King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom

⁷⁰Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 127, Canada


⁷¹Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, 55905, United States of America


SUPPLEMENTARY FIGURES

Supplementary Figure 1. Age at onset and age at death distribution. Violin plots showing age at onset (A) and age at death (B) are represented as well as box plots for each patient/control groups.




Supplementary Figure 2. Gene prioritization results for FTLD-TDP All. A visual summary of weighted evidence category scores for the prioritized genes within genome-wide significant and subthreshold loci for FTLD-TDP All GWAS. The leftmost squares indicate the locus index numbers which contain additional "S" patterns for the subthreshold loci, meanwhile others indicate the genome-wide significant loci. The types of evidence for each category are colored according to the six different domains to which they belonged. Weighted scores for each evidence category are rescaled to a 0-100 scale based on the maximum score a candidate gene can obtain from a category (see Supplementary Table 2). The darker colors represent higher scores in categories, while tier 1 prioritized genes are displayed in dark green and tier 2 prioritized genes are displayed in light green. Only tier 1 and tier 2 genes are shown for each locus, and all candidate genes considered and scored can be found in Supplementary Table 3. MAFs (based on gnomAD v4 non-Finnish European samples) and CADD (v1.7) PHRED scores for rare and/or proteinaltering rare variants are labeled in white within the respective squares. eQTL, expression QTL; sQTL, splicing QTL; mQTL, methylation QTL; pQTL, protein-expression QTL; haQTL, histone acetylation QTL; coloc, colocalization; eTWAS, expression transcriptome-wide association study; sTWAS, splicing transcriptome-wide association study; PWAS, proteome-wide association study; Mon. Mac., monocytes and macrophages; LCL, lymphoblastoid cell line; QTLCat, The eQTL Catalogue.





Prioritized Gene


Pric



Supplementary Figure 3. Gene prioritization results for FTLD-TDP A. A visual summary of weighted evidence category scores for the prioritized genes within genome-wide significant and subthreshold loci for FTLD-TDP A GWAS. The leftmost squares indicate the locus index numbers which contain additional "S" patterns for the subthreshold loci, meanwhile others indicate the genome-wide significant loci. The types of evidence for each category are colored according to the six different domains to which they belonged. Weighted scores for each evidence category are rescaled to a 0–100 scale based on the maximum score a candidate gene can obtain from a category (see Supplementary Table 2). The darker colors represent higher scores in categories, while tier 1 prioritized genes are displayed in dark green and tier 2 prioritized genes are displayed in light green. Only tier 1 and tier 2 genes are shown for each locus, and all candidate genes considered and scored can be found in Supplementary Table 3. MAFs (based on gnomAD v4 non-Finnish European samples) and CADD (v1.7) PHRED scores for rare and/or protein-altering rare variants are labeled in white within the respective squares. eQTL, expression QTL; sQTL, splicing QTL; mQTL, methylation QTL; pQTL, protein-expression QTL; haQTL, histone acetylation QTL; coloc, colocalization; eTWAS, expression transcriptome-wide association study; sTWAS, splicing transcriptome-wide association study; PWAS, proteome-wide association study; Mon. Mac., monocytes and macrophages; LCL, lymphoblastoid cell line; QTLCat, The eQTL Catalogue.

							Category			
				Lead variant eQTL -eQTL coloc & eTL.	Lead variant sQT -SQT coloc & STWAS	-cad variant ρQTL -ρQTL coloc & PWAS -Lead vari-		Lead variant ct-eQTL ct-eQTL coloc Lead variant ct-sQTL ct-sQTL coloc	Lead variant eQTL -eQTL coloc & eTVAS Lead variant sQTL -sQTL coloc & sTVAS -sQTL coloc & sTVAS -Gene Prioritization	
			-Rare -Nearest -Protein-altering	Lead variant еQT .eQTL coloc & er	Lead variant sQTL -SQTL coloc & STWA,	-cead variant рQTL -PQTL coloc & PWAS -Lead varia	-тент түт -түп coloc Lead variant haүт -haүп coloc	ct ct é	Lead variant eQT .eQT coloc & eTVMS .Lead variant sQT .sQTL coloc & sTVMS .Gene Prioritization	
			lteri	ant oc &	ant oc &	ant oc &	ant loc ant joc	ant , colo, ant ,	ant oc g oc g or ditizi	
			est in-a	Vari	Vari Col	Var Col		van קרוי רמה עמות	Var, Var, Var, Prii	
			.Rare .Nearest .Protein-a	eag	eau sQ71	-еад 2011 -еад		. ^{Lead} variant ct _i .ct-eQTL coloc .Lead variant ct _i . .ct.sQTL coloc	ead sQTI Sene	
			Variant		Bulk b	orain regions		Brain cell type	Mon/Mac/LCL	
		A 61	annotation	L	(AMP-	AD & GTEx)	100	(MiGA, Young, Bryois)	(EADB, GTEx, QTLCat)	
		A_S1 A_S2					100	66.7		
	KIRREL						100			
	PCNX2									
	TBC1D8						100			
	SCRN3			33.3				75		
	FARP2		0.6%							
	TRPC1	A_S7					100			
	FGFBP1	A_S8					100			
	IL31RA	A_S9					100		2	
	ADAM19	A_S10					100		2	
		A_S11					100			
	PRELID1								23.1 2	
		A_S13					100		2	
	TINAG									
	FMEM106B			88.9	66.7	100	100		53.8 40 1	
		A_S15					100			
ы	CSMD1				50		100			
Prioritized Gene	CENPP	A_S18		100	50	44.4	100	75	23.1 40 1	
ed	ASPN	A_S19					100		2 2	
ritiz	BSPRY	A_S20		33.3			100		1	
rio	PDLIM1	A_S21					100			
ш		A_S22					100		2	
	ARL14EP						100			
	ALKBH8			44.4						
		A_S25					100			
	MZT1		0.6%							
		A_S27					100			
	NKRD34C BCL2A1	A_S29			33.3				2	
		A_S30					100		2	
		A_S31						66.7	2	
	RNF166						100			
		A_S33					100			
	GRN FAM171A2	A4		100 100 33.3	50 33.3	44.4 100	100	75		
	PMAIP1								23.1 2	
		A_S35					100		2	
	WDR18	A_S36		44.4	50		100	100	30.8	
	EBF4	A_S37					100		2	
	COMT	A_S39					100		2	
			Per Category Re		0 25 50 7	Doma 5 100 or Typ	De mQTL-GWAS	Integration I haQTL-GWAS	eQTL-GWAS Integration Prioritized Sene Tier	
							Integration	integration de C		

Supplementary Figure 4. Gene prioritization results for FTLD-TDP B. A visual summary of weighted evidence category scores for the prioritized genes within genome-wide significant and subthreshold loci for FTLD-TDP B GWAS. The leftmost squares indicate the locus index numbers which contain additional "S" patterns for the subthreshold loci, meanwhile others indicate the genome-wide significant loci. The types of evidence for each category are colored according to the six different domains to which they belonged. Weighted scores for each evidence category are rescaled to a 0–100 scale based on the maximum score a candidate gene can obtain from a category (see Supplementary Table 2). The darker colors represent higher scores in categories, while tier 1 prioritized genes are displayed in dark green and tier 2 prioritized genes are displayed in light green. Only tier 1 and tier 2 genes are shown for each locus, and all candidate genes considered and scored can be found in Supplementary Table 3. MAFs (based on gnomAD v4 non-Finnish European samples) and CADD (v1.7) PHRED scores for rare and/or protein-altering rare variants are labeled in white within the respective squares. eQTL, expression QTL; sQTL, splicing QTL; mQTL, methylation QTL; pQTL, protein-expression QTL; haQTL, histone acetylation QTL; coloc, colocalization; eTWAS, expression transcriptome-wide association study; sTWAS, splicing transcriptome-wide association study; PWAS, proteome-wide association study; Mon. Mac., monocytes and macrophages; LCL, lymphoblastoid cell line; QTLCat, The eQTL Catalogue.



					(0		(0			egory		(a
				6	-Lead variant eQTL -eQTL coloc & eTWAS	-cad variant sQTL -sQTL coloc. ε	Lead variant рQTL -РQTL colo	Lead variant mor-	אור	- ^{Lead variant} haQTL . ^h aQTL coloc	Lead variant ct-eQTL ct-eQTL coloc Lead variant ct-sQTL -ct-sQTL coloc	Lead variant eQTL eQTL coloc & eTWAS Lead variant sQTL -SQTL coloc & sTWAS Gene Prioritization
			-Rare -Nearest -Protein-altari.	i in	ant el	ant s ₍	ant p	uc & I ant m	loc	- ^{Lead variant h_i -haQTL coloc}	Lead Variant ct-e -ct-eQTL coloc Lead Variant ct-s -ct-sQTL coloc	ant e oc & e ant s oc & s or tiza
			.Rare .Nearest .Protein-a		d var, T_Col	d var. T col	d var. T coi	d var	-mQTL coloc	d var. 17L cq	d var, QTL , d var, QTL ,	d var. T col T col T col
			-Rare -Neare. -Protei		-tea -eQ1	roa.	-pQ1	-Lea	дш-	- ^{Lea} -haç	Lea .ct.e .Lea .ct.s	Lea - Con-
			Variant annotation			Bu	lk brain reg MP-AD & G	ions			Brain cell type (MiGA, Young, Bryois)	Mon/Mac/LCL (EADB, GTEx, QTLCat)
	TNFSF8											23.1 2
	TCERG1L								100			2
	RNF141	_									66.7	2
	CEP126			JL	33.3							2
E	34GALNT3			JL					100			
		B_S39		J L		50						
	RAPGEF3			J L					100			
		B_S42		JL		50			100			23.1
	CRADD] L 1 -					100			
	FAM101A NCOR2								100 100			2
	GJB6	B_S45] [100			2
	PDS5B	- B3	0.5%] [
ъ	NKX2-1	B_S46] [100			2
en en	KLHDC2	- B_S47] [100			2
Prioritized Gene	PRKCH	B_S48] [100			2
itiz	EML5	B_S49] [100			2
rio	CIITA	B_S50] [66.7	2
<u>n</u>	ZFP90	B_S51] [100			30.8
	MAF	B_S52							100			2
	VPS53	B_S53] [33.3	50			100		100	53.8
	MYO15A	B_S54							100	100		
	GRN	B_S55] [44.4							
	UNC13A	- B4] [33.3							
	KCNC3	B_S56] [100			2
	ZNF816	B_S57] [100			2
	ZFP28	- B_S58] [23.1 2
	MGME1	B_S59			33.3							2
	SLC9A8 SPATA2				44.4 33.3				100			2 1
	ZFP64	B_S61] [100			2
	COMT	B_S62] [33.3				100			1
			Per Category I	Res	caled Score 0	25 50		Domain or Type	A m	ariant nnotation nQTL-GWAS ntegration	Integration Integration	QTL-GWAS ntegration Integration vrioritized sene Tier

Supplementary Figure 5. Gene prioritization results for FTLD-TDP C. A visual summary of weighted evidence category scores for the prioritized genes within genome-wide significant and subthreshold loci for FTLD-TDP C GWAS. The leftmost squares indicate the locus index numbers which contain additional "S" patterns for the subthreshold loci, meanwhile others indicate the genome-wide significant loci. The types of evidence for each category are colored according to the six different domains to which they belonged. Weighted scores for each evidence category are rescaled to a 0–100 scale based on the maximum score a candidate gene can obtain from a category (see Supplementary Table 2). The darker colors represent higher scores in categories, while tier 1 prioritized genes are displayed in dark green and tier 2 prioritized genes are displayed in light green. Only tier 1 and tier 2 genes are shown for each locus, and all candidate genes considered and scored can be found in Supplementary Table 3. MAFs (based on gnomAD v4 non-Finnish European samples) and CADD (v1.7) PHRED scores for rare and/or protein-altering rare variants are labeled in white within the respective squares. eQTL, expression QTL; sQTL, splicing QTL; mQTL, methylation QTL; pQTL, protein-expression QTL; haQTL, histone acetylation QTL; coloc, colocalization; eTWAS, expression transcriptome-wide association study; sTWAS, splicing transcriptome-wide association study; PWAS, proteome-wide association study; Mon. Mac., monocytes and macrophages; LCL, lymphoblastoid cell line; QTLCat, The eQTL Catalogue.

				s s	10	Category	-/	, s	S
		0	Lead variant eQTL -eQTL color 。	- с еТWAS Lead variant sQTL -sQTL coloc & sTWAS -Lead v	PQTL coloc & PWAS Lead vario		Lead variant ct-eQTL ct-eQTL coloc Lead variant ct-sQTT	^{-cc-} sq1L coloc Lead variant eq1L -eq1L coloc & e1TWAS	-ad variant sQTL -sQTL coloc & sTWAS Gene Prioritization
		.Rare .Nearest .Protein-altering	ant e,	ant si	ant p	лат т. 	Lead variant ct. .ct.eQTL coloc .Lead variant ct.	^{ct-s} QTL coloc Lead variant eQ -eQTL coloc & e. Lead	^{ant s} c & <u>;</u>
		sst in-al	Vari _č	Vari; Colc	^{carri} colc	лелт _т лорт, coloc Lead variant _t haqт, colo	varie TL c varie	TL c Varie Colc	Vari _i colc Prio
		.Rare .Nearest .Protein-a	ead QTL	еad QTL ead	QTL ead	nQT _I ead	ead t-eQ	P-sol	счи Эсне
	1	<u>لام</u> ح <u>ط</u> Variant	- <u>, ,</u>	<u> ଏ ଏ</u> Bulk br	역 년 ain regions	4 7 4	Brain cell type	<u>2 7 8 7</u> Mon/Mac/I	
		annotation		(AMP-A	D & GTEX)		(MiGA, Young, Bryo		QTLCat)
RRAGC				22.2		100			2
FAM72A				33.3					2
ADSS C1orf101	C_S3					100			2
PCYOX1					44.4				
DNAH7				50		100	75		
SGPP2						100			
AGAP1 UBE2F						100			2
	C_S10			33.3					
	C_S11					100			
	C_S12					100			
ANAPC13						100			2
CEP63 SERPINI1				50		100			2
NDUFB5			33.3	50					
	C_S16					100			
FAM134B						100			
	C_S23					100			
SKP1							75		2
Lioutiticed Gene Brioritized Gene GCM2 SYCP2L			44.4						
GCM2	C_S25					100			2
SYCP2L	C_S26					100			2
TNXB HLA-DQB1	C_S27					100 100			2
BTBD9						100			
CRIP3	6.620							30.8	2
ABCC10	0_329							23.1	2
FAM229B				33.3					2
	C_S31 C_S32					100			
ZAN KIAA1147						100		23.1	
	C_S34					100			
DNAJB6						100			
GATA4	C 626					100			2
LONRF1						100			2
	C_S37				44.4	100		23.1	
	C_S38 C_S39					100			
	C_S40					100			
TRAPPC9						100			
	C_S42					100			
		Domai		ation 📃 Inte	L-GWAS gration	pQTL-GWAS Integration	Per Category Rescaled		
		or Typ	e mQTL- Integra	GWAS haQ	TL-GWAS gration	Prioritized Gene Tier		0 25 50 7	5 100
			5						

Arriant annotation	Tead variant eQ1/2010 Tead variant eQ1/2010 	Bulk	P-AD & GT	ons	Lead variant hag TL	Lead Variant ct-sQT Lead Variant ct-sQT MIQUA Ct-eQT Ct-sQT coloc	Mon/Wac/CCL (EADB/ Del Janiant eQ11 Coloc & e1/MAS Lead Variant eQ11 Coloc & e1/MAS SQ11 coloc & e1/MAS SQ11 coloc & e1/MAS SQ11 coloc & e1/MAS	Tier 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Variant		Bulk (AMI	brain regi P-AD & GT	ons Ex) 100 100 100 100 100 100 100 100 100 10		Brain cell type	Mon/Mac/LCL (EADB, GTEX, QTLCat)	Tier 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
		50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50						2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
								2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
								2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
								1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
	44.4 33.3 33.3 33.3 33.3 33.3 33.3							2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	33.3 33.3 33.3 33.3 33.3 33.3 33.3							2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	33.3 33.3 33.3 33.3 33.3 33.3 33.3							1 2 2 2 2 2 2 2 2 2 2 2 2 2
	33.3 33.3 33.3 33.3 33.3 33.3 33.3							2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	33.3 33.3 33.3 33.3 33.3 33.3		44.4					2 2 2 2 2 2 2 2 2 2
	33.3 33.3 33.3 33.3		44.4					2 2 2 2 2
	33.3 33.3 33.3		44.4					2
	33.3	50	44.4				23.1	2
	33.3	50	44.4	100				2
	33.3	50	44.4	100				2
	00.0	50			1 1 1	75		2
				100		100	23.1	1
				100				2
				100				2
						66.7		2
		<u> </u>		100				2
				100				2
						75		2
				100				2
		50		100				1
	33.3							2
				100				2
	44.4			100			53.8	1
	33.3							2
	33.3						46.2	1
		33.3						2
				100				2
0.5%								1
		50		100				1
				100				2
			44.4			75		1
		33.3						2
					100			2
				33.3 33.3 33.3 1 44.4 1 33.3 1 33.3 1 33.3 1 33.3 1 33.3 1 33.3 1 33.3 1 1 33.3 1 33.3 1 1 1 1 1 1 1 1 1 1 1 50 1 1 1 1 1 44.4	33.3 1 33.3 1 44.4 100 33.3 1 33.3 1 33.3 1 33.3 1 1 33.3 1 33.3 1 100 1 33.3 1 100 1 100 1.5% 1 1 50 100 1 100 1 44.4	Image: Solution of the second seco	Image: Solution of the second seco	I 50 100 I I I I 50 100 I I I I 333 I I I I I I 100 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I

Supplementary Figure 6. RBPJL and L3MBTL1 RNA expression in brain tissue. A

Weighted gene co-expression network from the ROSMAP dataset and the BrainExp database showing that both genes are part of the same module. **B** Single nuclei RNA expression of RBPJL and L3MBTL1 genes from the Seattle Alzheimer's Disease Brain cell Atlas from middle temporal gyrus of 84 aged donors. The darkness of the color of each nucleus increases as the expression level becomes higher.

